Business
Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a
About this update from Neuphoria Therapeutics Inc.
[{"type":"text","content":"ADELAIDE, Australia and CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators for serious central nervous system (CNS) disorders with a high unmet medical need, today announced it will present data on BNC210 for the treatment of Social Anxiety Disorder (SAD) at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place Tuesday, May 30, 2023, through Friday, June 2, 2023, in Miami Beach, Florida. The presentation will include previously announced data from Phase 2 PREVAIL study of BNC210 for the acute treatment of SAD, which support the late-stage development of the drug for this indication. In addition, the presentation will highlight details on the trial’s public speaking task, the statistical analysis methodologies utilized for prespecified and post-hoc data analyses, previously undisclosed baseline characteristics, and gender subgroup analyses supporting similar treatment effects in males and females. Collectively, these analyses further support BNC210’s potential as a non-sedating anxiolytic for the acute treatment of SAD and may inform future registrational trial designs, including the selection of endpoints and population. “PREVAIL’s results demonstrate BNC210’s differentiated profile and potential to address a pressing unmet need, as there are currently no rapid-acting, non-sedating, non-habit-forming therapies approved for the acute treatment of anxiety episodes in SAD,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “We look forward to discussing these results with the global psychopharmacology community at ASCP, especially as we prepare for an FDA End of Phase 2 meeting to discuss a registrational program in SAD. With BNC210 supported by a robust clinical dataset and Fast Track Designation, we believe we are well positioned as we work to advance this potentially first and best-in-class therapy through the regulatory process and towards approval.” Details on the upcoming ASCP poster are shown below. Title: A Phase 2, Double-Blind, Placebo-Controlled Study for BNC210, an alpha7 Nicotinic Receptor Negative Allosteric Modulator (NAM) for the Acute Treatment of Social Anxiety Disorder (PREVAIL): Top-Line Eff...